NCT01710163

Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients

ARIQUELI: Potentiation of Quetiapine Treatment in Bipolar 1 Nonresponders Patients With Lithium or Aripiprazole

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: University of Sao Paulo · Academic / Other
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether Bipolar I Disorder refractory treatment with Quetiapine monotherapy could be better potentiated with Lithium or Aripiprazole. The investigators hypothesized that Lithium or Aripiprazole would provide similar compliance and tolerability in maintenance treatment.

Conditions

• Bipolar I Disorder

Interventions

Type	Name	Description
DRUG	Lithium	Starting at 300 mg daily, weekly dose will be adjusted according to blood serum level (between 0.5 -0.8mEq/l) according to efficacy and tolerability.
DRUG	Aripiprazole	Starting at 10 mg daily, dose will be adjusted up to 15 mg daily according to efficacy and tolerability.

Timeline

• Start date: 2012-06-01
• Primary completion: 2013-06-01
• Completion: 2015-06-01
• First posted: 2012-10-19
• Last updated: 2012-10-19

Locations

2 sites across 1 country: Brazil